Hong Kong and Brazil sign an MoU to exchange regulatory information on medicines and medical devices, supporting cooperation, innovation and stronger medical product regulation between the two jurisdictions.
Hong Kong and Brazil have agreed to deepen cooperation in the regulation of medical products, with their health authorities signing a Memorandum of Understanding (MoU) to strengthen regulatory information exchange and collaboration.
Hong Kong’s Department of Health (DH) and Brazil’s National Health Surveillance Agency (ANVISA) signed the MoU in Hong Kong. The agreement covers cooperation on the regulation of medicines, including biological and traditional medicines, as well as medical devices.
Also Read: Advanced Materials: Next-Gen Protection for Land, Sea & Air Ops
The MoU establishes a mechanism for information exchange and regulatory cooperation between the two authorities. The initiative is intended to support the sharing of regulatory experience and technical knowledge while strengthening efforts to protect and promote public health in both jurisdictions.
The signing was witnessed by Hong Kong Secretary for Health Professor Lo Chung-mau. Hong Kong Director of Health Dr Ronald Lam and ANVISA Director-President Leandro Safatle signed the agreement.
According to Hong Kong’s Department of Health, the cooperation follows a bilateral meeting held in May 2026 between Hong Kong health officials, Brazil’s Health Minister Alexandre Padilha and Safatle during the 79th World Health Assembly in Geneva. The discussions focused on strengthening cooperation in medical product regulation and supporting more efficient approval frameworks for innovative products.
ANVISA is a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Hong Kong said cooperation with the Brazilian regulator would support its efforts to align its medical product regulatory framework with international standards.
The collaboration also comes as Hong Kong prepares to establish its Centre for Medical Products Regulation (CMPR) in 2026. The centre is expected to strengthen the city’s regulatory capabilities for medicines and medical devices and expand cooperation with overseas regulatory authorities.
Also Read: Quality as the Quintessence: Raising the Bar for ASEAN's Industrial Sector
ANVISA’s delegation also visited the Chinese Medicine Hospital of Hong Kong and the Government Chinese Medicines Testing Institute during its stay. The visits provided an opportunity to examine clinical services, facilities and internationally recognised testing standards for Chinese medicines, creating a basis for potential cooperation in traditional medicine.